Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann W Morgan

Showing results (51-60 of 136) with videos related to

Pageof 14
Sort By:
Plos One|January 12, 2012
FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapyDawn L Cooper, Stephen G Martin, James I Robinson, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
Rheumatology (Oxford, England)|August 24, 2011
Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factorsSarah L Mackie, Bhaskar Dasgupta, Lesley Hordon, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathwaysCatherine Potter, Heather J Cordell, Anne Barton, et al.
Rheumatology (Oxford, England)|October 3, 2022
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritisRyan M Hum, Pauline Ho, Nisha Nair, et al.
Lancet (London, England)|August 28, 2015
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
The Pharmacogenomics Journal|September 1, 2018
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisJonathan Massey, Darren Plant, Kimme Hyrich, et al.
Annals of the Rheumatic Diseases|August 25, 2009
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive diseaseJames I Robinson, Jennifer H Barrett, John C Taylor, et al.
Rheumatology (Oxford, England)|June 30, 2023
A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measuresStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosusGisela Orozco, Steve Eyre, Anne Hinks, et al.
Pageof 14

Showing results (51-60 of 136) with videos related to

Sort By:
Pageof 14
Plos One|January 12, 2012
FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapyDawn L Cooper, Stephen G Martin, James I Robinson, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
Rheumatology (Oxford, England)|August 24, 2011
Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factorsSarah L Mackie, Bhaskar Dasgupta, Lesley Hordon, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathwaysCatherine Potter, Heather J Cordell, Anne Barton, et al.
Rheumatology (Oxford, England)|October 3, 2022
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritisRyan M Hum, Pauline Ho, Nisha Nair, et al.
Lancet (London, England)|August 28, 2015
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
The Pharmacogenomics Journal|September 1, 2018
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisJonathan Massey, Darren Plant, Kimme Hyrich, et al.
Annals of the Rheumatic Diseases|August 25, 2009
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive diseaseJames I Robinson, Jennifer H Barrett, John C Taylor, et al.
Rheumatology (Oxford, England)|June 30, 2023
A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measuresStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosusGisela Orozco, Steve Eyre, Anne Hinks, et al.
Pageof 14